Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Université de Montréal
Deal Size : Undisclosed
Deal Type : Collaboration
CQDM and Epitopea Develop CryptoMap™ Platform For RNA Immunotherapies
Details : The collaboration will examine the feasibility of developing new RNA-based immunotherapies to effectively treat patients with lung and ovarian cancers using CryptoMap platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 26, 2024
Lead Product(s) : RNA-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Université de Montréal
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cryptigen-based Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Innovate UK
Deal Size : $0.6 million
Deal Type : Funding
Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme
Details : The net proceeds from the funding will be used to advance the development of company's Cryptigen immunotherapeutics, discovered by Epitopea’s CryptoMap platform, for cancer.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 12, 2024
Lead Product(s) : Cryptigen-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Innovate UK
Deal Size : $0.6 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?